Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 185


ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.

Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord AA, Lyerly HK, Morse MA, Philip R.

Clin Exp Immunol. 2011 Mar;163(3):324-32. doi: 10.1111/j.1365-2249.2010.04298.x. Epub 2010 Dec 22.


The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.

Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT.

J Immunother. 2008 Jan;31(1):7-17.


MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.


Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA dimer-based artificial antigen-presenting cells.

Xiaobing J, Xiaoling L, Ruen L, Fangcheng Z, Hongyang Z.

Cancer Biother Radiopharm. 2007 Dec;22(6):826-35.


Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M.

J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125.


Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.


Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.


Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.

Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG.

Clin Cancer Res. 1999 Dec;5(12):4214-23.


Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.

Matsueda S, Wang M, Weng J, Li Y, Yin B, Zou J, Li Q, Zhao W, Peng W, Legras X, Loo C, Wang RF, Wang HY.

PLoS One. 2012;7(9):e45756. doi: 10.1371/journal.pone.0045756. Epub 2012 Sep 20.


HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.


HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.

Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH.

Scand J Immunol. 2013 Sep;78(3):248-57. doi: 10.1111/sji.12083.


Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O.

Exp Hematol. 2006 Apr;34(4):486-96.


Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.

Cancer Res. 2000 Oct 1;60(19):5522-8.


T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.

Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15877-81. Epub 2012 Sep 10.


Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.

Kiessling A, Stevanovic S, Füssel S, Weigle B, Rieger MA, Temme A, Rieber EP, Schmitz M.

Br J Cancer. 2004 Mar 8;90(5):1034-40.


Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC.

Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 3.


[Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].

Li W, Cui H, Chang XH, Cheng HY, Cheng YX, Feng J, Fu TY.

Zhonghua Fu Chan Ke Za Zhi. 2008 Oct;43(10):764-9. Chinese.


A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.

Yamamoto K, Trad A, Baumgart A, Hüske L, Lorenzen I, Chalaris A, Grötzinger J, Dechow T, Scheller J, Rose-John S.

Biochem J. 2012 Jul 1;445(1):135-44. doi: 10.1042/BJ20120433.


Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.

Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC.

Int Immunol. 2003 Jun;15(6):751-63.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk